Wounds : a compendium of clinical research and practice · 2013
Platelet-rich plasma in skin ulcer treatment.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cobos Campos Raquel, Parraza Diez Naiara, Aizpuru Barandiaran Felipe
Аннотация
INTRODUCTION: Chronic vascular ulcers are associated with a high use of resources. Conventional treatment consists of wound cleansing, necrotic tissue debridement, prevention, diagnosis, and, if necessary, treatment of infection and dressing application; although conventional treatment has limited effectiveness with wound healing (around 15-30%).8-11 Platelet-rich plasma, used in various fields of medicine, improves chronic vascular ulcer results, but is more expensive.
METHODS: A cost-effectiveness analysis was performed using a 48-week period comparing plateletrich plasma with standard care. A meta-analysis of papers identified by a literature search was done.
RESULTS: A combined measure of effectiveness at 12 weeks for each treatment option was calculated and served as the basis for estimating the probability of healing at 48 weeks with a Markov model.
CONCLUSIONS: The probability of healing and associated costs were 56% and €5224 using platelet-rich plasma and 31% and €5133 with usual care. The incremental cost that must be assumed to achieve additional healing with platelet-rich plasma is €364. .
METHODS: A cost-effectiveness analysis was performed using a 48-week period comparing plateletrich plasma with standard care. A meta-analysis of papers identified by a literature search was done.
RESULTS: A combined measure of effectiveness at 12 weeks for each treatment option was calculated and served as the basis for estimating the probability of healing at 48 weeks with a Markov model.
CONCLUSIONS: The probability of healing and associated costs were 56% and €5224 using platelet-rich plasma and 31% and €5133 with usual care. The incremental cost that must be assumed to achieve additional healing with platelet-rich plasma is €364. .